Evidence map›Paper›PMID 7512981›Full record

ArticleThe Journal of clinical investigation1994

Similar levels of mRNA from the W1282X and the delta F508 cystic fibrosis alleles, in nasal epithelial cells.

T Shoshani, E Kerem, A Szeinberg, A Augarten, Y Yahav, D Cohen, J Rivlin, A Tal, B Kerem

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Cystic Fibrosis, CFTR, and Colorectal Cancer.International journal of molecular sciences · 2020
    Review
  3. Article
  4. Decreased mRNA and protein stability of W1282X limits response to modulator therapy.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019
    Article
  5. Article
  6. Article
  7. Restoration of W1282X CFTR activity by enhanced expression.American journal of respiratory cell and molecular biology · 2007
    Article
  8. Update and Review: Cystic Fibrosis.Journal of genetic counseling · 1999
    Article
  9. Novel pharmacologic therapies for cystic fibrosis.The Journal of clinical investigation · 1999
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

T ShoshaniDepartment of Genetics, Hebrew University of Jerusalem, Israel.
E Kerem
A Szeinberg
A Augarten
Y Yahav
D Cohen
J Rivlin
A Tal
B Kerem
Hebrew University of Jerusalem · ILCarmel Medical Center · ILShaare Zedek Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effect of nonsense mutations on mRNA levels is variable. The levels of some mRNAs are not affected and truncated proteins are produced, while the levels of others are severely decreased and null phenotypes are observed. The effect on mRNA levels is important for the understanding of phenotype-genotype association. Cystic fibrosis (CF) is a lethal autosomal recessive disease with variable clinical presentation. Recently, two CF patients with mild pulmonary disease carrying nonsense mutations (R553X, W1316X) were found to have severe deficiency of mRNA. In the Jewish Ashkenazi CF patient population, 60% of the chromosomes carry a nonsense mutation, W1282X. Patients homozygous for this mutation have severe disease presentation with variable pulmonary disease. The presence of CF transcripts in a group of patients homozygous and heterozygous for this mutation was studied by reverse transcriptase PCR of various regions of the gene. Subsequent hybridization to specific CF PCR probes and densitometry analysis indicated that the CF mRNA levels in patients homozygous for the W1282X mutation are not significantly decreased by the mutation. mRNA levels were compared for patients heterozygous for the W1282X mutation. The relative levels of mRNA with the W1282X, and the delta F508 or the normal alleles, were similar in each patient. These results indicate that the severe clinical phenotype of patients carrying the W1282X mutation is not due to a severe deficiency of mRNA. In addition, the severity, progression, and variability of the pulmonary disease are affected by other, as yet unknown factors.

Indexed as

AllelesMutationBase SequenceCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansMembrane ProteinsMolecular Sequence DataNasal MucosaPolymerase Chain ReactionRNA, MessengerCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorMembrane ProteinsRNA, Messenger

Identifiers

PMID7512981
PMCPMC294164
OpenAlexW2136473266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.